Use of PET is widespread and increasing in the United States, mainly for oncologic applications. In November 2006, the National Comprehensive Cancer Network (NCCN) gathered a panel of experts to review the literature and develop clinical recommendations for using PET scans in lymphoma and non–small cell lung, breast, and colorectal cancers. However, because its use is not restricted to these diseases, and evidence is accumulating for its application in other types of cancers, NCCN convened a second meeting in December 2008 to expand on the initial report. A multidisciplinary panel met to discuss the current data on PET application for various tumor types, including genitourinary, gynecologic, pancreatic, hepatobiliary, thyroid, brain, small cell lung, gastric, and esophageal cancers, and sarcoma and myeloma. This report summarizes the proceedings of this meeting, including discussions of the background of PET, the role of PET in oncology, principles of PET use, emerging applications, and possible future developments.

If the inline PDF is not rendering correctly, you can download the PDF file here.

References

  • 1

    PodoloffDAAdvaniRHAllredC. NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw2007;5(Suppl 1):S122; quiz S23–22.

    • Search Google Scholar
    • Export Citation
  • 2

    CasneufVDelrueLKellesA. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?Acta Gastroenterol Belg2007;70:331338.

    • Search Google Scholar
    • Export Citation
  • 3

    DirisamerAHalpernBSFloryD. Performance of integrated FDG-PET/contrast-enhanced CT in the staging and restaging of colorectal cancer: comparison with PET and enhanced CT. Eur J Radiol2009; in press.

    • Search Google Scholar
    • Export Citation
  • 4

    GerthHUJuergensKUDirksenU. Significant benefit of multimodal imaging: PET/CT compared with PET alone in staging and follow-up of patients with Ewing tumors. J Nucl Med2007;48:19321939.

    • Search Google Scholar
    • Export Citation
  • 5

    KitajimaKMurakamiKYamasakiE. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT. Eur J Nucl Med Mol Imaging2009; in press.

    • Search Google Scholar
    • Export Citation
  • 6

    LardinoisDWederWHanyTF. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med2003;348:25002507.

    • Search Google Scholar
    • Export Citation
  • 7

    StrobelKHeinrichSBhureU. Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer. J Nucl Med2008;49:14081413.

    • Search Google Scholar
    • Export Citation
  • 8

    TateishiUYamaguchiUSekiK. Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging. Radiology2007;245:839847.

    • Search Google Scholar
    • Export Citation
  • 9

    AntochGSaoudiNKuehlH. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol2004;22:43574368.

    • Search Google Scholar
    • Export Citation
  • 10

    WarburgO. The Metabolism of Tumors. New York: Richard R. Smith; 1931.

  • 11

    GatenbyRAGilliesRJ. Why do cancers have high aerobic glycolysis?Nat Rev Cancer2004;4:891899.

  • 12

    KelloffGJHoffmanJMJohnsonB. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res2005;11:27852808.

    • Search Google Scholar
    • Export Citation
  • 13

    MankoffDAEaryJFLinkJM. Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond. Clin Cancer Res2007;13:34603469.

    • Search Google Scholar
    • Export Citation
  • 14

    ThompsonJEThompsonCB. Putting the rap on Akt. J Clin Oncol2004;22:42174226.

  • 15

    MachedaMLRogersSBestJD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol2005;202:654662.

    • Search Google Scholar
    • Export Citation
  • 16

    EaryJFO’SullivanFPowitanY. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging2002;29:11491154.

    • Search Google Scholar
    • Export Citation
  • 17

    OshidaMUnoKSuzukiM. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. Cancer1998;82:22272234.

    • Search Google Scholar
    • Export Citation
  • 18

    VansteenkisteJFischerBMDoomsCMortensenJ. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol2004;5:531540.

    • Search Google Scholar
    • Export Citation
  • 19

    RobbinsRJWanQGrewalRK. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab2006;91:498505.

    • Search Google Scholar
    • Export Citation
  • 20

    CMS final decision memo: Available at: https://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?from2=viewdecisionmemo.asp&id=218&. Accessed April 7 2009.

    • Search Google Scholar
    • Export Citation
  • 21

    HillnerBELiuDColemanRE. The National Oncologic PET Registry (NOPR): design and analysis plan. J Nucl Med2007;48:19011908.

  • 22

    HillnerBESiegelBALiuD. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol2008;26:21552161.

    • Search Google Scholar
    • Export Citation
  • 23

    HillnerBESiegelBAShieldsAF. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med2008;49:19281935.

    • Search Google Scholar
    • Export Citation
  • 24

    LevineMNJulianJA. Registries that show efficacy: good, but not good enough. J Clin Oncol2008;26:53165319.

  • 25

    ChattertonBEHo ShonIBaldeyA. Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging2009;36:354361.

    • Search Google Scholar
    • Export Citation
  • 26

    ScottAMGunawardanaDHBartholomeuszD. PET changes management and improves prognostic stratification in patients with head and neck cancer: results of a multicenter prospective study. J Nucl Med2008;49:15931600.

    • Search Google Scholar
    • Export Citation
  • 27

    ScottAMGunawardanaDHKelleyB. PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective study. J Nucl Med2008;49:14511457.

    • Search Google Scholar
    • Export Citation
  • 28

    ScottAMGunawardanaDHWongJ. Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging2009;36:347353.

    • Search Google Scholar
    • Export Citation
  • 29

    MolBWLijmerJGEversJLBossuytPM. Characteristics of good diagnostic studies. Semin Reprod Med2003;21:1725.

  • 30

    van TinterenHHoekstraOSSmitEF. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet2002;359:13881393.

    • Search Google Scholar
    • Export Citation
  • 31

    MaziakDDarlingGEInculetRI. A randomized controlled trial (RCT) of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) versus conventional imaging (CI) in staging potentially resectable non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 7502.

    • Search Google Scholar
    • Export Citation
  • 32

    HerderGJKramerHHoekstraOS. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol2006;24:18001806.

    • Search Google Scholar
    • Export Citation
  • 33

    SobhaniITiretELebtahiR. Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer2008;98:875880.

    • Search Google Scholar
    • Export Citation
  • 34

    van HeijlMOmlooJMvan Berge HenegouwenMI. NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial). BMC Med Phys2008;8:3.

    • Search Google Scholar
    • Export Citation
  • 35

    ShankarLKHoffmanJMBacharachS. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med2006;47:10591066.

    • Search Google Scholar
    • Export Citation
  • 36

    HodgsonNCGulenchynKY. Is there a role for positron emission tomography in breast cancer staging?J Clin Oncol2008;26:712720.

  • 37

    AlaviJBAlaviAChawlukJ. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer1988;62:10741078.

  • 38

    De WitteOLevivierMViolonP. Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma. Neurosurgery1996;39:470476; discussion 476–477.

    • Search Google Scholar
    • Export Citation
  • 39

    PadmaMVSaidSJacobsM. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol2003;64:227237.

  • 40

    StuppRMasonWPvan den BentMJ. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med2005;352:987996.

  • 41

    BrandsmaDStalpersLTaalW. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol2008;9:453461.

    • Search Google Scholar
    • Export Citation
  • 42

    LanglebenDDSegallGM. PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med2000;41:18611867.

  • 43

    ChaoSTSuhJHRajaS. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer2001;96:191197.

    • Search Google Scholar
    • Export Citation
  • 44

    ChenWSilvermanDH. Advances in evaluation of primary brain tumors. Semin Nucl Med2008;38:240250.

  • 45

    HustinxRPourdehnadMKaschtenBAlaviA. PET imaging for differentiating recurrent brain tumor from radiation necrosis. Radiol Clin North Am2005;43:3547.

    • Search Google Scholar
    • Export Citation
  • 46

    SpenceAMMuziMMankoffDA. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. J Nucl Med2004;45:16531659.

    • Search Google Scholar
    • Export Citation
  • 47

    TsuyuguchiNSunadaIIwaiY. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible?J Neurosurg2003;98:10561064.

    • Search Google Scholar
    • Export Citation
  • 48

    GrosuALWeberWAFranzM. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys2005;63:511519.

    • Search Google Scholar
    • Export Citation
  • 49

    TralinsKSDouglasJGStelzerKJ. Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med2002;43:16671673.

    • Search Google Scholar
    • Export Citation
  • 50

    AttanasiFBelcariNCamardaM. Experimental validation of the filtering approach for dose monitoring in proton therapy at low energy. Phys Med2008;24:102106.

    • Search Google Scholar
    • Export Citation
  • 51

    KnopfAParodiKPaganettiH. Quantitative assessment of the physical potential of proton beam range verification with PET/CT. Phys Med Biol2008;53:41374151.

    • Search Google Scholar
    • Export Citation
  • 52

    ParodiKFerrariASommererFPaganettiH. Clinical CT-based calculations of dose and positron emitter distributions in proton therapy using the FLUKA Monte Carlo code. Phys Med Biol2007;52:33693387.

    • Search Google Scholar
    • Export Citation
  • 53

    ChenJCheongJHYunMJ. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer2005;103:23832390.

    • Search Google Scholar
    • Export Citation
  • 54

    ShahMAYeungHTrocolaR. The characteristics and utility of FDG-PET/CT scans in patients with localized gastric cancer (GC) [abstract]. Presented at the 2007 Gastrointestinal Cancers Symposium; January 19–21, 2007; Orlando, Florida. Abstract 2.

    • Search Google Scholar
    • Export Citation
  • 55

    YangQMKawamuraTItohH. Is PET-CT suitable for predicting lymph node status for gastric cancer?Hepatogastroenterology2008;55:782785.

  • 56

    YunMLimJSNohSH. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT. J Nucl Med2005;46:15821588.

  • 57

    FlamenPLerutAVan CutsemE. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol2000;18:32023210.

    • Search Google Scholar
    • Export Citation
  • 58

    van WestreenenHLWesterterpMBossuytPM. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol2004;22:38053812.

    • Search Google Scholar
    • Export Citation
  • 59

    van WestreenenHLWesterterpMSloofGW. Limited additional value of positron emission tomography in staging oesophageal cancer. Br J Surg2007;94:15151520.

    • Search Google Scholar
    • Export Citation
  • 60

    WesterterpMvan WestreenenHLReitsmaJB. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy—systematic review. Radiology2005;236:841851.

    • Search Google Scholar
    • Export Citation
  • 61

    DowneyRJAkhurstTIlsonD. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol2003;21:428432.

    • Search Google Scholar
    • Export Citation
  • 62

    FlamenPVan CutsemELerutA. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol2002;13:361368.

    • Search Google Scholar
    • Export Citation
  • 63

    OttKFinkUBeckerK. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol2003;21:4604610.

    • Search Google Scholar
    • Export Citation
  • 64

    WeberWAOttKBeckerK. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol2001;19:30583065.

    • Search Google Scholar
    • Export Citation
  • 65

    LordickFOttKKrauseBJ. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol2007;8:797805.

    • Search Google Scholar
    • Export Citation
  • 66

    Clinicaltrials.gov.A phase II trial of preoperative irinotecan cisplatin and radiation in esophageal cancer. Available at: http://clinicaltrials.gov/ct/show/NCT00316862. Accessed February 9 2009.

    • Search Google Scholar
    • Export Citation
  • 67

    EffertPJBaresRHandtS. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol1996;155:994998.

    • Search Google Scholar
    • Export Citation
  • 68

    HoferCLaubenbacherCBlockT. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol1999;36:3135.

    • Search Google Scholar
    • Export Citation
  • 69

    LiuIJZafarMBLaiYH. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology2001;57:108111.

    • Search Google Scholar
    • Export Citation
  • 70

    KangDEWhiteRLJrZugerJH. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol2004;171:18061809.

    • Search Google Scholar
    • Export Citation
  • 71

    GofritONMishaniEOreviM. Contribution of 11C-choline positron emission tomography/computerized tomography to preoperative staging of advanced transitional cell carcinoma. J Urol2006;176:940944; discussion 944.

    • Search Google Scholar
    • Export Citation
  • 72

    MorrisMJAkhurstTOsmanI. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology2002;59:913918.

    • Search Google Scholar
    • Export Citation
  • 73

    FrickeEMachtensSHofmannM. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging2003;30:607611.

    • Search Google Scholar
    • Export Citation
  • 74

    KaoCHHsiehJFTsaiSC. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res2000;20:21892192.

    • Search Google Scholar
    • Export Citation
  • 75

    PicchioMTreiberUBeerAJ. Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings. J Nucl Med2006;47:938944.

    • Search Google Scholar
    • Export Citation
  • 76

    DrieskensOOyenRVan PoppelH. FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging2005;32:14121417.

  • 77

    AnjosDAEtchebehereECRamosCD. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. J Nucl Med2007;48:764770.

    • Search Google Scholar
    • Export Citation
  • 78

    LiuIJLaiYHEspirituJI. Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy. Urol Int2006;77:6975.

    • Search Google Scholar
    • Export Citation
  • 79

    SafaeiAFiglinRHohCK. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer. Clin Nephrol2002;57:5662.

    • Search Google Scholar
    • Export Citation
  • 80

    WuHCYenRFShenYY. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas—a preliminary report. J Cancer Res Clin Oncol2002;128:503506.

    • Search Google Scholar
    • Export Citation
  • 81

    MajhailNSUrbainJLAlbaniJM. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol2003;21:39954000.

    • Search Google Scholar
    • Export Citation
  • 82

    YenTCNgKKMaSY. Value of dual-phase 2-fluoro-2-deoxy-d-glucose positron emission tomography in cervical cancer. J Clin Oncol2003;21:36513658.

    • Search Google Scholar
    • Export Citation
  • 83

    LinWCHungYCYehLS. Usefulness of (18) F-fluorodeoxyglucose positron emission tomography to detect para-aortic lymph nodal metastasis in advanced cervical cancer with negative computed tomography findings. Gynecol Oncol2003;89:7376.

    • Search Google Scholar
    • Export Citation
  • 84

    XueFLinLLDehdashtiF. F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecol Oncol2006;101:147151.

    • Search Google Scholar
    • Export Citation
  • 85

    RisumSHogdallCLoftA. The diagnostic value of PET/CT for primary ovarian cancer--a prospective study. Gynecol Oncol2007;105:145149.

  • 86

    SuzukiRMiyagiETakahashiN. Validity of positron emission tomography using fluoro-2-deoxyglucose for the preoperative evaluation of endometrial cancer. Int J Gynecol Cancer2007;17:890896.

    • Search Google Scholar
    • Export Citation
  • 87

    ChaoAChangTCNgKK. 18F-FDG PET in the management of endometrial cancer. Eur J Nucl Med Mol Imaging2006;33:3644.

  • 88

    SchwarzJKSiegelBADehdashtiFGrigsbyPW. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA2007;298:22892295.

    • Search Google Scholar
    • Export Citation
  • 89

    GoldMA. PET in cervical cancer—implications for ‘staging,’ treatment planning, assessment of prognosis, and prediction of response. J Natl Compr Canc Netw2008;6:3745.

    • Search Google Scholar
    • Export Citation
  • 90

    YenTCSeeLCChangTC. Defining the priority of using 18F-FDG PET for recurrent cervical cancer. J Nucl Med2004;45:16321639.

  • 91

    HusainAAkhurstTLarsonS. A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration. Gynecol Oncol2007;106:177180.

    • Search Google Scholar
    • Export Citation
  • 92

    MurakamiMMiyamotoTIidaT. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer. Int J Gynecol Cancer2006;16(Suppl 1):99107.

    • Search Google Scholar
    • Export Citation
  • 93

    ThrallMMDeLoiaJAGallionHAvrilN. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol2007;105:1722.

    • Search Google Scholar
    • Export Citation
  • 94

    SimcockBNeeshamDQuinnM. The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol2006;103:271276.

  • 95

    MangiliGPicchioMSironiS. Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. Eur J Nucl Med Mol Imaging2007;34:658666.

    • Search Google Scholar
    • Export Citation
  • 96

    Positron emission tomography for nine cancers (bladder, brain, cervical, kidney, ovarian, pancreatic, prostate, small cell lung, testicular). Technology assessment report prepared by UAEPC for AHRQ. Available at: http://www.cms.hhs.gov/determinationprocess/downloads/id54TA.pdf. Accessed February 24 2009.

    • Search Google Scholar
    • Export Citation
  • 97

    SchirrmeisterHBommerMBuckAK. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging2002;29:361366.

    • Search Google Scholar
    • Export Citation
  • 98

    SchirrmeisterHBuckAKBergmannL. Positron emission tomography (PET) for staging of solitary plasmacytoma. Cancer Biother Radiopharm2003;18:841845.

    • Search Google Scholar
    • Export Citation
  • 99

    MileshkinLBlumRSeymourJF. A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma. Eur J Haematol2004;72:3237.

    • Search Google Scholar
    • Export Citation
  • 100

    NanniCZamagniEFarsadM. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging2006;33:525531.

    • Search Google Scholar
    • Export Citation
  • 101

    Breyer RJIIIMulliganMESmithSE. Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma. Skeletal Radiol2006;35:632640.

    • Search Google Scholar
    • Export Citation
  • 102

    FontiRSalvatoreBQuarantelliM. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. J Nucl Med2008;49:195200.

    • Search Google Scholar
    • Export Citation
  • 103

    DurieBGWaxmanADD’AgnoloAWilliamsCM. Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med2002;43:14571463.

  • 104

    BangSChungHWParkSW. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol2006;40:923929.

    • Search Google Scholar
    • Export Citation
  • 105

    ZimnyMBaresRFassJ. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med1997;24:678682.

    • Search Google Scholar
    • Export Citation
  • 106

    SpertiCPasqualiCDecetG. F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study. J Gastrointest Surg2005;9:2228; discussion 28–29.

    • Search Google Scholar
    • Export Citation
  • 107

    BrandtKRCharboneauJWStephensDH. CT- and US-guided biopsy of the pancreas. Radiology1993;187:99104.

  • 108

    ChangKJNguyenPEricksonRA. The clinical utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic carcinoma. Gastrointest Endosc1997;45:387393.

    • Search Google Scholar
    • Export Citation
  • 109

    MertzHRSechopoulosPDelbekeDLeachSD. EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma. Gastrointest Endosc2000;52:367371.

    • Search Google Scholar
    • Export Citation
  • 110

    FarmaJMSantillanAAMelisM. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol2008;15:24652471.

    • Search Google Scholar
    • Export Citation
  • 111

    HeinrichSGoerresGWSchaferM. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg2005;242:235243.

    • Search Google Scholar
    • Export Citation
  • 112

    CorveraCUBlumgartLHAkhurstT. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg2008;206:5765.

    • Search Google Scholar
    • Export Citation
  • 113

    KimJYKimMHLeeTY. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol2008;103:11451151.

    • Search Google Scholar
    • Export Citation
  • 114

    PetrowskyHWildbrettPHusarikDB. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol2006;45:4350.

    • Search Google Scholar
    • Export Citation
  • 115

    Rodriguez-FernandezAGomez-RioMLlamas-ElviraJM. Positron-emission tomography with fluorine-18-fluoro-2-deoxy-D-glucose for gallbladder cancer diagnosis. Am J Surg2004;188:171175.

    • Search Google Scholar
    • Export Citation
  • 116

    AndersonCDRiceMHPinsonCW. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg2004;8:9097.

    • Search Google Scholar
    • Export Citation
  • 117

    SeoSHatanoEHigashiT. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma. Surgery2008;143:769777.

    • Search Google Scholar
    • Export Citation
  • 118

    ParkJWKimJHKimSK. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med2008;49:19121921.

    • Search Google Scholar
    • Export Citation
  • 119

    WudelLJJrDelbekeDMorrisD. The role of [18F] fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg2003;69:117124; discussion 124–116.

    • Search Google Scholar
    • Export Citation
  • 120

    RufJLopez HanninenEOettleH. Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI. Pancreatology2005;5:266272.

    • Search Google Scholar
    • Export Citation
  • 121

    ChenYKHsiehDSLiaoCS. Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence. Anticancer Res2005;25:47194725.

    • Search Google Scholar
    • Export Citation
  • 122

    YangSHSuhKSLeeHW. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl2006;12:16551660.

    • Search Google Scholar
    • Export Citation
  • 123

    SeoSHatanoEHigashiT. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res2007;13:427433.

    • Search Google Scholar
    • Export Citation
  • 124

    ChikamotoATsujiTTakamoriH. The diagnostic efficacy of FDG-PET in the local recurrence of hilar bile duct cancer. J Hepatobiliary Pancreat Surg2006;13:403408.

    • Search Google Scholar
    • Export Citation
  • 125

    AndersonGSBrinkmannFSoulenMC. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med2003;28:192197.

    • Search Google Scholar
    • Export Citation
  • 126

    PaudyalBOriuchiNPaudyalP. Early diagnosis of recurrent hepatocellular carcinoma with 18F-FDG PET after radiofrequency ablation therapy. Oncol Rep2007;18:14691473.

    • Search Google Scholar
    • Export Citation
  • 127

    ZhaoMWuPHZengYX. [Evaluating efficacy of transcatheter arterial chemo-embolization combined with radiofrequency ablation on patients with hepatocellular carcinoma by 18FDG-PET/CT]. Ai Zheng2005;24:11181123[in Chinese].

    • Search Google Scholar
    • Export Citation
  • 128

    NiewegOEPruimJvan GinkelRJ. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med1996;37:257261.

  • 129

    SchulteMBrecht-KraussDHeymerB. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. J Nucl Med2000;41:16951701.

  • 130

    FranziusCDaldrup-LinkHESciukJ. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol2001;12:479486.

    • Search Google Scholar
    • Export Citation
  • 131

    LucasJDO’DohertyMJWongJC. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg Br1998;80:441447.

    • Search Google Scholar
    • Export Citation
  • 132

    FranziusCSciukJDaldrup-LinkHE. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med2000;27:13051311.

    • Search Google Scholar
    • Export Citation
  • 133

    DemetriGDvon MehrenMBlankeCD. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med2002;347:472480.

    • Search Google Scholar
    • Export Citation
  • 134

    DemetriGDvan OosteromATGarrettCR. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet2006;368:13291338.

    • Search Google Scholar
    • Export Citation
  • 135

    Van den AbbeeleAD. The lessons of GIST—PET and PET/CT: a new paradigm for imaging. Oncologist2008;13(Suppl 2):813.

  • 136

    AntochGKanjaJBauerS. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med2004;45:357365.

    • Search Google Scholar
    • Export Citation
  • 137

    van den AbbeeleAMelenevskyYde VriesD. Imaging kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST) [abstract]. J Clin Oncol2005;23(Suppl 1):Abstract 9006.

    • Search Google Scholar
    • Export Citation
  • 138

    PriorJOMontemurroMOrcurtoMV. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol2009;27:439445.

    • Search Google Scholar
    • Export Citation
  • 139

    BradleyJDDehdashtiFMintunMA. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol2004;22:32483254.

    • Search Google Scholar
    • Export Citation
  • 140

    BrinkISchumacherTMixM. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging2004;31:16141620.

    • Search Google Scholar
    • Export Citation
  • 141

    ChinRJrMcCainTWMillerAA. Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. Lung Cancer2002;37:16.

    • Search Google Scholar
    • Export Citation
  • 142

    HauberHPBohuslavizkiKHLundCH. Positron emission tomography in the staging of small-cell lung cancer: a preliminary study. Chest2001;119:950954.

    • Search Google Scholar
    • Export Citation
  • 143

    KamelEMZwahlenDWyssMT. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med2003;44:19111917.

    • Search Google Scholar
    • Export Citation
  • 144

    KutVSpiesWSpiesS. Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). Am J Clin Oncol2007;30:4550.

    • Search Google Scholar
    • Export Citation
  • 145

    SchumacherTBrinkIMixM. FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med2001;28:483488.

  • 146

    ShenYYShiauYCWangJJ. Whole-body 18F-2-deoxyglucose positron emission tomography in primary staging small cell lung cancer. Anticancer Res2002;22:12571264.

    • Search Google Scholar
    • Export Citation
  • 147

    VinjamuriMCraigMCampbell-FontaineA. Can positron emission tomography be used as a staging tool for small-cell lung cancer?Clin Lung Cancer2008;9:3034.

    • Search Google Scholar
    • Export Citation
  • 148

    LeeHYChungJKJeongJM. Comparison of FDG-PET findings of brain metastasis from non-small-cell lung cancer and small-cell lung cancer. Ann Nucl Med2008;22:281286.

    • Search Google Scholar
    • Export Citation
  • 149

    PanditNGonenMKrugLLarsonSM. Prognostic value of [18F] FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging2003;30:7884.

    • Search Google Scholar
    • Export Citation
  • 150

    DaviesLWelchHG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA2006;295:21642167.

  • 151

    Albores-SaavedraJHensonDEGlazerESchwartzAM. Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype—papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol2007;18:17.

    • Search Google Scholar
    • Export Citation
  • 152

    PrymaDASchoderHGonenM. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hurthle cell thyroid cancer patients. J Nucl Med2006;47:12601266.

    • Search Google Scholar
    • Export Citation
  • 153

    LoweVJMullanBPHayID. 18F-FDG PET of patients with Hurthle cell carcinoma. J Nucl Med2003;44:14021406.

  • 154

    KatzSCShahaA. PET-associated incidental neoplasms of the thyroid. J Am Coll Surg2008;207:259264.

  • 155

    GoughJScott-CoombesDFausto PalazzoF. Thyroid incidentaloma: an evidence-based assessment of management strategy. World J Surg2008;32:12641268.

    • Search Google Scholar
    • Export Citation
  • 156

    OngSCSchoderHPatelSG. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med2007;48:501507.

    • Search Google Scholar
    • Export Citation
  • 157

    GiraudetALVanelDLeboulleuxS. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab2007;92:41854190.

    • Search Google Scholar
    • Export Citation
  • 158

    LeboulleuxSSchroederPRSchlumbergerMLadensonPW. The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nat Clin Pract Endocrinol Metab2007;3:112121.

    • Search Google Scholar
    • Export Citation
  • 159

    LeboulleuxSSchroederPRBusaidyNL. Assessment of the incremental value of recombinant TSH stimulation before FDG PET/CT imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab2009;94:13101316.

    • Search Google Scholar
    • Export Citation
  • 160

    WangWLarsonSMFazzariM. Prognostic value of [18F] fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab2000;85:11071113.

    • Search Google Scholar
    • Export Citation
  • 161

    FeineULietzenmayerRHankeJP. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med1996;37:14681472.

  • 162

    HungMCWuHSKaoCH. F18-fluorodeoxyglucose positron emission tomography in detecting metastatic papillary thyroid carcinoma with elevated human serum thyroglobulin levels but negative I-131 whole body scan. Endocr Res2003;29:169175.

    • Search Google Scholar
    • Export Citation
  • 163

    SchluterBBohuslavizkiKHBeyerW. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med2001;42:7176.

    • Search Google Scholar
    • Export Citation
  • 164

    BogsrudTVKarantanisDNathanMA. 18F-FDG PET in the management of patients with anaplastic thyroid carcinoma. Thyroid2008;18:713719.

  • 165

    JuweidMEStroobantsSHoekstraOS. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol2007;25:571578.

    • Search Google Scholar
    • Export Citation
  • 166

    HillnerBESiegelBAShieldsAF. The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry. Cancer2009;115:410418.

    • Search Google Scholar
    • Export Citation
  • 167

    EsthappanJChaudhariSSantanamL. Prospective clinical trial of positron emission tomography/computed tomography image-guided intensity-modulated radiation therapy for cervical carcinoma with positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys2008;72:11341139.

    • Search Google Scholar
    • Export Citation
  • 168

    PirotteBGoldmanSMassagerN. Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. J Neurosurg2004;101:476483.

    • Search Google Scholar
    • Export Citation
  • 169

    BadingJRShieldsAF. Imaging of cell proliferation: status and prospects. J Nucl Med2008;49(Suppl 2):64S80S.

  • 170

    RischinDHicksRJFisherR. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol2006;24:20982104.

    • Search Google Scholar
    • Export Citation

Article Information

PubMed

Google Scholar

Related Articles

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 32 32 9
PDF Downloads 18 18 12
EPUB Downloads 0 0 0